Table 5.
Secondary outcomes regarding satisfaction level, length of PO hospital stays and adverse events
| Duloxetine (n = 48) | Placebo (n = 48) | P value | |
|---|---|---|---|
| Satisfaction level† (no.[%] of patients) | |||
| Extremely satisfied | 19 (40%) | 11 (23%) | |
| Very satisfied | 21 (44%) | 17 (35%) | |
| Somewhat satisfied | 5 (10%) | 8 (17%) | |
| Neither satisfied nor dissatisfied | 2 (4%) | 6 (13%) | |
| Somewhat dissatisfied | 1 (2%) | 4 (8%) | |
| Very dissatisfied | 0 | 2 (4%) | |
| Extremely dissatisfied | 0 | 0 | |
| length of PO hospital staysa (h) | 63.4 ± 17.6 | 70.7 ± 23.7 | 0.089 |
| Adverse Events† (no.[%] of patients) | |||
| Nausea and vomiting | 8 (17%) | 7 (15%) | 0.779 |
| Dry mouth | 4 (8%) | 2 (4%) | 0.677 |
| Insomnia | 5 (10%) | 6 (13%) | 0.749 |
| Somnolence | 6 (13%) | 3 (6%) | 0.486 |
| Constipation | 7 (15%) | 9 (19%) | 0.584 |
| Dizziness | 3 (6%) | 4 (8%) | 1.000 |
| Fatigue | 5 (10%) | 7 (15%) | 0.537 |
aData are given as the mean ± standard deviation. †Data are given as the number (percentage) of patients